We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+5.61%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$489M
AUM Growth
-$71.9M
Cap. Flow
-$18.9M
Cap. Flow %
-3.87%
Top 10 Hldgs %
88.2%
Holding
39
New
2
Increased
1
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$18.1M
2
ALMS
Alumis Inc
ALMS
+$7.25M
3
AURA icon
Aura Biosciences
AURA
+$5.85M

Top Sells

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$7.97M
2
SLRN
ACELYRIN
SLRN
+$6.23M
3
UPB
Upstream Bio Inc
UPB
+$5.76M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.37M
5
LENZ
LENZ Therapeutics
LENZ
+$4.99M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$5.71B
$199M 40.66%
5,612,896
– –
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.35B
$76.8M 15.7%
5,674,916
– –
SEPN
3
Septerna Inc
SEPN
$1.49B
$33.3M 6.81%
3,149,128
– –
KLRS
4
Kalaris Therapeutics
KLRS
$88.7M
$30.6M 6.25%
11,448,081
– –
NGNE icon
5
Neurogene
NGNE
$696M
$25.7M 5.25%
1,717,127
– –
CRGX
6
DELISTED
CARGO Therapeutics
CRGX
$18.2M 3.72%
4,415,689
– –
UPB
7
Upstream Bio Inc
UPB
$349M
$15.8M 3.24%
1,443,231
-623,915
-30% -$5.76M
ALMS
8
Alumis Inc
ALMS
$3.57B
$14.4M 2.95%
4,801,370
+1,534,872
+47% +$7.25M
LENZ
9
LENZ Therapeutics
LENZ
$172M
$10.1M 2.06%
343,012
-183,378
-35% -$4.99M
PVLA
10
Palvella Therapeutics
PVLA
$1.98B
$7.66M 1.57%
339,743
-339,743
-50% -$7.97M
GOSS icon
11
Gossamer Bio
GOSS
$66.5M
$7.54M 1.54%
6,130,268
– –
ACLX
12
DELISTED
Arcellx
ACLX
$6.68M 1.37%
101,457
-33,819
-25% -$2.11M
AURA icon
13
Aura Biosciences
AURA
$729M
$6.26M 1.28%
+1,000,000
New +$5.85M
NKTX icon
14
Nkarta
NKTX
$162M
$6.25M 1.28%
3,768,035
– –
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$5.98M 1.22%
675,504
-292,023
-30% -$2.57M
JBIO
16
Jade Biosciences
JBIO
$1.22B
$5.31M 1.09%
+531,163
New +$18.1M
ZYME icon
17
Zymeworks
ZYME
$1.68B
$3.89M 0.8%
310,300
-356,367
-53% -$4.25M
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$7B
$3.19M 0.65%
50,476
-87,642
-63% -$5.37M
VTVT icon
19
vTv Therapeutics
VTVT
$121M
$3.1M 0.63%
206,784
– –
CTNM
20
Contineum Therapeutics
CTNM
$526M
$2.34M 0.48%
588,816
– –
SRZN icon
21
Surrozen
SRZN
$229M
$2.16M 0.44%
241,400
– –
STRO icon
22
Sutro Biopharma
STRO
$379M
$1.57M 0.32%
219,681
– –
TNGX icon
23
Tango Therapeutics
TNGX
$4.34B
$1.08M 0.22%
210,000
-420,000
-67% -$1.04M
HLVX
24
DELISTED
HilleVax
HLVX
$795K 0.16%
399,637
– –
TERN
25
DELISTED
Terns Pharmaceuticals
TERN
$755K 0.15%
202,348
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q2 2025 Portfolio in Review

As of Q2 2025, Samsara BioCapital held 39 positions worth $489M, down 13% from $561M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Samsara BioCapital withdrew a net $18.9M in Q2 2025, closing 10 positions and reducing 9 holdings. Its most notable exit was ACELYRIN, an estimated $6.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Jade Biosciences worth $5.31M.

  • Samsara BioCapital's largest Q2 2025 buy was Jade Biosciences: 531,163 shares worth $5.31M.
  • Samsara BioCapital added most to Alumis Inc in Q2 2025, an estimated $7.25M increase.
  • Samsara BioCapital's biggest Q2 2025 reduction was Palvella Therapeutics, cutting an estimated $7.97M.
  • Samsara BioCapital fully exited ACELYRIN in Q2 2025, selling an estimated $6.23M.
  • Samsara BioCapital's ten largest holdings make up 88% of its $489M portfolio in Q2 2025.
  • Samsara BioCapital opened 2 new positions and closed 10 in Q2 2025.
  • Samsara BioCapital's portfolio value fell 13% quarter-over-quarter to $489M.

Based on Samsara BioCapital's 13F filing for Q2 2025, filed 14 Aug 2025.